BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 1, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2004

View Archived Issues

Gabapentin delays ejaculation in a case of PE / News in Context

Read More

New angiotensin II receptor agonists covered by Vicore patent

Read More

New GLP-2 derivatives and their use in gastrointestinal disorders

Read More

GSK researchers identify new ROCK inhibitors for use in cardiovascular and other disorders

Read More

Merck claims prostaglandin analogues as EP4 receptor agonists for ocular and bone conditions

Read More

Emory University patents CXCR4 antagonists and their use in cancer

Read More

Novel method for treatment for neutrophil-mediated conditions

Read More

Pharmacokinetic interactions with UK-427857 studied

Read More

Selective TRPV1 receptor antagonist shows analgesic effect in vivo

Read More

CAT and AstraZeneca form alliance in inflammatory disorders

Read More

Nonendocannabinoid inhibitor of anadamide inactivation shows analgesic effects in pain model

Read More

Alfacell and NCI pursue development of RN-321

Read More

Novel 1beta-methylcarbapanem shows promising antibacterial activity

Read More

Vesicare approved by FDA

Read More

Poor bioavailability results for R-803 in phase I/II HCV study

Read More

Multitarget antimalarial vaccine effective in non-human primates

Read More

BEYOND study of Betaferon recommended to continue

Read More

NDA submission for indiplon modified release

Read More

New Roche study investigates response rates to HCV therapy in Latinos

Read More

Synta closes financing round

Read More

Bayer signs development agreement for longer-acting Kogenate

Read More

EHT-0202 to enter phase IIa proof-of-concept study in Alzheimer's in 2005

Read More

European approval for Bayer's acquisition of Roche consumer health business

Read More

TMC-114 active against resistant HIV-1

Read More

Long-term antiviral activity of TMC-125 seen in HIV-infected patients

Read More

Liarozole reported safe and effective in the treatment of ichthyosis and psoriasis

Read More

Cilansetron improves quality of life of patients with diarrhea-predominant IBS

Read More

Study of interferon gamma-1b in idiopathic pulmonary fibrosis continues

Read More

Clinical data confirm the benefits of AGI-1067 in atherosclerosis

Read More

Phase II data on the therapeutic benefits of dexanabinol in CABG-associated cognitive impairment

Read More

Results of phase I study of FG-3019 in idiopathic pulmonary fibrosis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing